tetraxetan
Sign in to saveAlso known as NSC 681107, 1,4,7,10-Dota, ,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, 2,2',2',2'''-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetryl)tetraacetic acid, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, DOTA acid
chemical compound
Research
1,554 papers- FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
- Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.Drugs of today (Barcelona, Spain : 1998) · 2023
- Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.Molecular diagnosis & therapy · 2022
- Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.Expert review of anticancer therapy · 2022
- (177)Lu-Vipivotide Tetraxetan ((177)Lu-PSMA-617, Pluvicto) Therapy.Journal of nuclear medicine technology · 2022
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has part
- hydrogen
- Mass
- 404.190714
Show 2 more facts
- chemical formula
- C₁₆H₂₈N₄O₈
- canonical SMILES
- C1CN(CCN(CCN(CCN1CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O
via Wikidata · CC0